SOURCE: Ablynx

April 27, 2008 17:13 ET

Ablynx Announces Senior Management Change

GHENT, BELGIUM--(Marketwire - April 27, 2008) - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, has announced that Dr Hennie Hoogenboom will be stepping down from his position as Chief Scientific Officer and member of the Executive Committee.

Dr Hoogenboom joined Ablynx in 2005 and has contributed significantly to building up the robust Nanobody® technology platform and to the discovery of Nanobodies® for internal and partnered therapeutic programmes. Dr Hoogenboom will work closely together with the Executive Committee to assure an effective and smooth transition of responsibilities.

Dr Edwin Moses, Chief Executive Officer and Chairman commented: "I wish to thank Hennie for his contribution to Ablynx. We appreciate his contributions and wish him well in his future endeavors." In line with its strategy to transition from a technology platform to a product Company, Ablynx has initiated an executive search to strengthen its senior management team with individuals with extensive experience in the discovery and development of pharmaceuticals. Commenting on this search, Dr Moses said: "With its extensive resources, excellent validated biologics platform technology and developing product pipeline, Ablynx offers unique opportunities to the right individuals."

Hennie Hoogenboom commented: "Working at Ablynx for the past years has been an extraordinary and unique opportunity, with the Company growing from a small biotech firm to a public company with multiple large partnerships with pharmaceutical companies, I'm honored to have been part of this phase of the Company and to have worked with such talented and dedicated colleagues."

As the Company continues to advance its product portfolio to grow a broader product pipeline, its aim is to file 5 IND-equivalents over the next 5 years. Ablynx's lead programme, ALX-0081 has successfully completed a first Phase I study and the Company is progressing this development candidate to the next stage, with a Phase 1b multi-dose study in patients due to start shortly.

Contact Information

  • For more information, please contact:

    College Hill Life Sciences - for UK/International media enquiries:
    Sue Charles, Justine Lamond, John Mc Intyre
    t: +44 (0)20 7457 2020
    f: +44 (0)20 7866 7900
    e: Email Contact

    Dr. Edwin Moses
    Chairman and CEO
    t: +32 (0)9 262 00 07
    m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
    e: Email Contact

    Eva-Lotta Allan
    Chief Business Officer
    t: +32 (0)9 262 00 75
    m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
    e: Email Contact

    Copyright © Hugin AS 2008. All rights reserved.